These results manifest the combination treatment of dorzagliatin with sitagliptin improved glucose-stimulated insulin secretion (GSIS) to achieve a greater glucose-lowering effect than either monotherapy, thus indicating the synergic potential for glycemic control in T2D patients. This evidence concerns the gene INS and type 2 diabetes mellitus.